Lixisenatide belongs to the new generation of drugs called GLP-1R agonists, which are making a breakthrough in the treatment of type 2 diabetes and obesity.
A well-known diabetes drug may slow the progression of Parkinson’s disease, according to scientists in France.
In a study conducted by researchers with 156 patients newly diagnosed with the disease, it was found that the type 2 diabetes drug called lixisenatide (lixisenatide) slow down the progression of motor symptoms caused by condition.
Recently, another drug for type 2 diabetes called exenatidehas been found to help slow the progression of the motor symptoms of Parkinson’s disease.
Vasilios Meissner, the study’s lead researcher from the University Hospital of Bordeaux in France, said the findings are exciting.
“We have to be cautious about interpretation and applicability at this stage, but it’s really a very, very clear and strong message that we’ve never seen except in the exenatide clinical trial,” he said.
The research
THE lixisenatide belongs to the new generation of drugs called GLP-1R agonists, which is making a breakthrough in the treatment of type 2 diabetes and obesity.
The participating patients were randomly divided into two groups. Participants in both groups continued to take medication for the disease. However, one group also received a daily injection of lixisenatide, while the other received a placebo infusion (placebo). Before, during and after the study, the patients underwent tests in which their motor symptoms were assessed.
The findings showed that after 12 months, those who had received lixisenatide had no worsening of his motor symptomss. In contrast, those who had received the placebo showed a worsening of their symptoms, of the order of three points on the MDS-UPDRS part III rating scale – a modest difference but considered clinically significant.
The difference remained two months after the clinical trial was completed.
This, the researchers say, suggests that lixisenatide doesn’t just slow down symptoms, it protects the brain from neuron lossn. However, there was a downside, as about half of the participants who received lixisenatide reported nausea and 13% reported vomiting.
The researchers noted that further research is needed to confirm the clinical trial findings.
The findings of the study were published in the New England Journal of Medicine.
Source :Skai
I have worked in the news industry for over 10 years. I have a vast amount of experience in covering health news. I am also an author at News Bulletin 247. I am highly experienced and knowledgeable in this field. I am a hard worker and always deliver quality work. I am a reliable source of information and always provide accurate information.
